![]() ![]() ![]() ![]() Subramaniam RM, DeMora L, Yao M, Yom SS, Gillison M, Caudell JJ, Waldron J, Xia P, Chung C, Truong MT, Echevarria M, Chan JW, Geiger JL, Mell L, Seaward S, Thorstad WL, Beitler JJ, Sultanem K, Blakaj D, Le QT.If you believe you are eligible for one of these trials or studies, please call Intervention: IGRT () IMRT () M3814 Peposertib () Phase I Trial With Expansion Cohort Of DNA-PK Inhibition And IMRT In Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head And Neck Squamous Cell Carcinoma (HNSCC) Intervention: Cetuximab () Erbitux (Cetuximab) NBTXR3 () Not Applicable () Intervention: Atezolizumab (Tecentriq) Cetuximab () Erbitux (Cetuximab) Taxotere (docetaxel) cisplatin () docetaxel ()Ī Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigators Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck University of Texas Houston School of Medicine - MD.University of Alabama, Birmingham - Radiation Oncology.Caudell is a member of the RTOG/NRG H&N Steering Committee, RTOG 1016 QA Committee, National Comprehensive Cancer Network (NCCN) H&N Panel and H&N Radiation Oncology Sub-Committee. Caudell currently serves as H&N Service Chief and has added the H&N SBRT Program. Lecture topics for the Department of Otolaryngology of the University of South Florida and Moffitt H&N Symposium include “Chemoradiation of the Head and Neck” and “Current Management of Locally Advanced HPV-Negative Head & Neck Cancer.” Dr. Caudell works closely with the Radiation Oncology Residency Clinical Competency Committee and provides consistent mentorship to our Radiation Oncology Residents through clinic rotations and lectures. Caudell has been instrumental in development of the H&N/Endocrine Clinical Pathways, serves on the MMG Revenue Cycle Committee and Center of Excellence in Cancer Imaging and Technology, and has been a member of Moffitt’s Scientific Symposium Committee. Caudell’s role in many collaborative projects is to provide clinical expertise regarding the outcomes and toxicities associated with radiation treatment for H&N cancers. He also has performed research in treatment disparities and novel radiation delivery techniques for head and neck cancer. From a clinical standpoint, his work on treatment planning and dysphagia following radiation treatment has been nationally recognized. Caudell’s research has focused primarily on treatment outcomes with respect to both cancer control and toxicity. Caudell continues his research through retrospective analysis of patients treated for H&N malignancies (primary and metastatic).ĭr. He is also PI of a grant to predict the benefit of post-operative radiotherapy in H&N cancer using a gene expression signature of tumor radiosensitivity. Caudell is PI on a phase I dose escalation trial of H&N SBRT with concurrent chemotherapy for patients with recurrent, unresectable H&N cancer. Caudell is currently co-PI on the national NRG HN-002 prospective clinical trial testing methods to reduce toxicity for patients with low risk oropharyngeal HPV positive H&N cancer. Research interests include prediction of radiation sensitivity, evaluation of novel radiosensitizers and radioprotectants, as well as the use of technology to improve radiation delivery for head and neck cancer.ĭr. Caudell’s clinical interests include treatment of head and neck cancer and cutaneous malignancies with radiotherapy. Caudell joined the Moffitt Faculty in October 2011 as Assistant Member in the Head and Neck program, Radiation Oncology specializing in the treatment of head and neck cancers.ĭr. Cancer Focus: Esophageal Cancer, Head and Neck Cancer, Oral Cavity or Throat Cancer, Throat Cancer, Thyroid Cancerĭr.
0 Comments
Leave a Reply. |